EUVIMEDEUVIMED entdecken
Crossref

Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study

Javier García-Abellán iD, José A García iD, Ronald Galdámez, María José Gosalbes, Marta Fernández-González iD, Sergio Padilla iD, Paula Mascarell iD, Guillermo Telenti, Félix Gutiérrez iD, Mar Masiá iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Javier García-Abellán und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Alicante, Spain. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Weight Gain, HIV Infections, HIV Integrase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Spanish National Plan for Scientific and Technical Research and Innovation, European Regional Development Fund, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the relationship between the gut microbiota composition and significant weight gain in virologically-suppressed people with HIV (PWH) on antiretroviral therapy.

Methods

This 5-year prospective longitudinal study included virologically-suppressed PWH receiving regimens based on the integrase strand transfer inhibitors (INSTIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs). Body weight was measured annually, with significant weight gain defined as a ≥10% increase between consecutive measurements or compared to baseline. Gut microbiota profiling was conducted using 16S rRNA sequencing (V3–V4 regions) via the Illumina MiSeq platform.

Results

202 participants were recruited, with 169 completing the 240-week follow-up. Among these, 63 remained on INSTI-based, 79 on NNRTI-based and 27 on NNRTI + INSTI-based regimens. Median (interquartile range (IQR)) 5-year weight gain was 1.3 (−2.8 to 4.5) kg. Significant weight gain occurred in 70 (34.7%) participants, including 20 (9.9%) with ≥10% gain between consecutive measurements and 50 (24.8%) from baseline. No significant differences were observed in adjusted α- and β-diversity indices between groups defined by weight gain. Adjusted analysis of compositions of microbiomes with bias correction 2 model showed that weight gain was associated with the genera Dialister and Tyzzerella_4, whereas Phascolarctobacterium was enriched in those without significant weight gain. While overall weight gain did not differ between INSTI-based and NNRTI-based groups, participants on INSTIs-based regimens showed higher relative abundances of bacteria linked to weight gain, like Tyzzerella_4 (0.05% versus 0.02%, P = 0.017) and Lactobacillus (0.29% versus 0.22%, P = 0.009).

Conclusions

Significant weight gain in the PWH is associated with distinct gut microbiota profiles. The enrichment of weight gain-associated taxa, such as Tyzzerella_4 and Lactobacillus, in individuals on INSTI-based regimens suggests a potential microbiota-mediated mechanism modulating metabolic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeWeight GainHIV InfectionsHIV Integrase InhibitorsHumansLongitudinal StudiesMaleFemaleMiddle AgedProspective StudiesAdultRNA, Ribosomal, 16SBacteria

Substanzen

HIV Integrase InhibitorsRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Infectious Diseases Unit, Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Alicante, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Infectious Diseases Unit, Hospital General Universitario de Elche, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Alicante, Spain.
  • Genomics and Health Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, and CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

ORCID-Profile: Javier García-Abellán, José A García, Marta Fernández-González, Sergio Padilla, Paula Mascarell, Félix Gutiérrez, Mar Masiá

Förderung

  • Spanish National Plan for Scientific and Technical Research and Innovation
  • European Regional Development Fund
  • Instituto de Salud Carlos III
  • Consorcio Centro de Investigación Biomédica en Red
  • Ministerio de Ciencia e Innovación and European Union-NextGenerationEU
  • UMH-FISABIO
  • Generalitat Valenciana
  • Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana

Zitieren

APA

García-Abellán, J., García, J. A., Galdámez, R., Gosalbes, M. J., Fernández-González, M., Padilla, S., Mascarell, P., Telenti, G., Gutiérrez, F., & Masiá, M. (2025). Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf182

Vancouver

García-Abellán J, García JA, Galdámez R, Gosalbes MJ, Fernández-González M, Padilla S, et al. Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf182

BibTeX
@article{GarcaAbelln2025,
  author = {García-Abellán, Javier and García, José A and Galdámez, Ronald and Gosalbes, María José and Fernández-González, Marta and Padilla, Sergio and Mascarell, Paula and Telenti, Guillermo and Gutiérrez, Félix and Masiá, Mar},
  title = {Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf182}
}
Kostenlos starten →